Lumenis (NASDAQ: LMNS) and The Spectranetics Corporation (NASDAQ:SPNC) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitabiliy, risk, analyst recommendations, valuation, earnings and institutional ownership.
This table compares Lumenis and The Spectranetics Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|The Spectranetics Corporation||-24.26%||-95.88%||-14.51%|
This is a breakdown of current ratings for Lumenis and The Spectranetics Corporation, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|The Spectranetics Corporation||0||8||1||0||2.11|
The Spectranetics Corporation has a consensus price target of $34.14, suggesting a potential downside of 11.20%. Given The Spectranetics Corporation’s higher probable upside, analysts plainly believe The Spectranetics Corporation is more favorable than Lumenis.
Institutional and Insider Ownership
92.0% of The Spectranetics Corporation shares are held by institutional investors. 3.7% of The Spectranetics Corporation shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Lumenis and The Spectranetics Corporation’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|The Spectranetics Corporation||$284.59 million||5.88||-$17.85 million||($1.59)||-24.18|
Lumenis has higher revenue, but lower earnings than The Spectranetics Corporation.
The Spectranetics Corporation beats Lumenis on 5 of the 8 factors compared between the two stocks.
Lumenis Ltd. (Lumenis) is a provider of energy-based, minimally invasive clinical solutions. The Company operates through three segments: surgical, ophthalmic and aesthetic. The Company offers energy-based solutions for medically necessary and elective procedures, primarily for the aging population. Its solutions include the holmium laser, the Lumenis Pulse 120H, used for urologic applications; the VersaPulse PowerSuite platform which uses holmium lasers for urologic applications; the M22 multi-energy, a multi-application platform for the treatment of various skin conditions, and the Selecta multi-modality platform for retinal, secondary cataract and glaucoma therapies. It offers products to hospitals, outpatient clinics, ambulatory surgery centers, physicians’ offices, private clinics and aesthetic chains. Its locations include Yokneam, Israel, where surgical and aesthetic products are manufactured, and Salt Lake City, Utah, where ophthalmic products are manufactured.
About The Spectranetics Corporation
The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads. Its geographic segments are U.S. Medical and International Medical. Its product offerings in U.S. Medical segment include medical devices used in minimally invasive procedures within the cardiovascular system, including fiber-optic devices and non-fiber-optic products (disposables), an excimer laser system (equipment) and the service of the excimer laser system (service). Its products are used in multiple vascular procedures, including peripheral atherectomy, crossing arterial blockages, coronary atherectomy and thrombectomy. Its International Medical segment is primarily engaged in distribution activities.
What are top analysts saying about Lumenis Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Lumenis Ltd and related companies.